ABCELLERA BIOLOGICS (8QQ) — Capital Reinvestment Ratio
Latest as of December 2022:
0.26x
ABCELLERA BIOLOGICS (8QQ) has a Capital Reinvestment Ratio of 0.26x as of December 2022, meaning it reinvests 0% of its operating cash flow (€277.36 Million) in capital expenditures (€72.66 Million). See cash generation quality of ABCELLERA BIOLOGICS to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.26x
Capex / Operating Cash Flow
Operating Cash Flow
€277.36 Million
EUR
Capital Expenditures
€72.66 Million
EUR
Data as of
Dec 2022
Most recent filing
ABCELLERA BIOLOGICS Capital Reinvestment Ratio (2021–2022)
This chart tracks ABCELLERA BIOLOGICS's Capital Reinvestment Ratio across 2 annual periods.
Annual Capital Reinvestment Ratio for ABCELLERA BIOLOGICS (2021–2022)
Year-by-year Capital Reinvestment Ratio for ABCELLERA BIOLOGICS from 2021 to 2022. For live market cap and broader valuation context, see 8QQ company net worth.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2022 | 0.26x | €277.36 Million | €72.66 Million | ▲ +9.6% |
| 2021 | 0.24x | €244.58 Million | €58.45 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow